Journal article

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors

Mayur Garg, Simon G Royce, John S Lubel

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2020

Abstract

We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

Grants

Awarded by Broad Medical Research Program


Funding Acknowledgements

The original study (Garg M, Royce SG, Tikellis C, et al Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut. 2020) was supported by a grant from the Broad Medical Research Program (Grant Reference IBD-0360).